O
1.70
-0.04 (-2.30%)
| Previous Close | 1.74 |
| Open | 1.74 |
| Volume | 2,933,769 |
| Avg. Volume (3M) | 4,745,491 |
| Market Cap | 1,141,635,072 |
| Price / Sales | 1.45 |
| Price / Book | 0.870 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -7.46% |
| Operating Margin (TTM) | -18.05% |
| Diluted EPS (TTM) | -0.080 |
| Quarterly Revenue Growth (YOY) | 1.00% |
| Total Debt/Equity (MRQ) | 36.94% |
| Current Ratio (MRQ) | 3.43 |
| Operating Cash Flow (TTM) | -183.49 M |
| Levered Free Cash Flow (TTM) | -129.55 M |
| Return on Assets (TTM) | -8.12% |
| Return on Equity (TTM) | -3.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bearish |
| Diagnostics & Research (Global) | Mixed | Bearish | |
| Stock | Opko Health, Inc. | Bullish | Mixed |
AIStockmoo Score
1.1
| Analyst Consensus | 5.0 |
| Insider Activity | 2.5 |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.10 |
|
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 55.26% |
| % Held by Institutions | 29.89% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 3.00 (HC Wainwright & Co., 76.47%) | Buy |
| Median | 2.63 (54.71%) | |
| Low | 2.25 (Barrington Research, 32.35%) | Buy |
| Average | 2.63 (54.71%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 1.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Apr 2025 | 3.00 (76.47%) | Buy | 1.53 |
| 19 Mar 2025 | 3.00 (76.47%) | Buy | 1.86 | |
| Barrington Research | 12 Mar 2025 | 2.25 (32.35%) | Buy | 1.78 |
| 28 Feb 2025 | 2.25 (32.35%) | Buy | 1.74 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FROST PHILLIP MD ET AL | 1.68 | - | 250,000 | 421,000 |
| Aggregate Net Quantity | 250,000 | |||
| Aggregate Net Value ($) | 421,000 | |||
| Aggregate Avg. Buy ($) | 1.68 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | Officer | 01 Apr 2025 | Buy (+) | 100,000 | 1.66 | 166,000 |
| FROST PHILLIP MD ET AL | Officer | 28 Mar 2025 | Buy (+) | 150,000 | 1.70 | 255,000 |
| Date | Type | Details |
|---|---|---|
| 04 Apr 2025 | Announcement | OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program |
| 17 Mar 2025 | Announcement | OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders |
| 11 Mar 2025 | Announcement | Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses |
| 27 Feb 2025 | Announcement | OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results |
| 13 Feb 2025 | Announcement | OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |